187 related articles for article (PubMed ID: 24716804)
1. NILCO biomarkers in breast cancer from Chinese patients.
Colbert LS; Wilson K; Kim S; Liu Y; Oprea-Ilies G; Gillespie C; Dickson T; Newman G; Gonzalez-Perez RR
BMC Cancer; 2014 Apr; 14():249. PubMed ID: 24716804
[TBL] [Abstract][Full Text] [Related]
2. Notch, IL-1 and leptin crosstalk outcome (NILCO) is critical for leptin-induced proliferation, migration and VEGF/VEGFR-2 expression in breast cancer.
Guo S; Gonzalez-Perez RR
PLoS One; 2011; 6(6):e21467. PubMed ID: 21731759
[TBL] [Abstract][Full Text] [Related]
3. Leptin-induced Notch and IL-1 signaling crosstalk in endometrial adenocarcinoma is associated with invasiveness and chemoresistance.
Daley-Brown D; Harbuzariu A; Kurian AA; Oprea-Ilies G; Gonzalez-Perez RR
World J Clin Oncol; 2019 Jun; 10(6):222-233. PubMed ID: 31367531
[TBL] [Abstract][Full Text] [Related]
4. Type II Endometrial Cancer Overexpresses NILCO: A Preliminary Evaluation.
Daley-Brown D; Oprea-Iles G; Vann KT; Lanier V; Lee R; Candelaria PV; Quarshie A; Pattillo R; Gonzalez-Perez RR
Dis Markers; 2017; 2017():8248175. PubMed ID: 28659656
[TBL] [Abstract][Full Text] [Related]
5. Role of Notch, IL-1 and leptin expression in colorectal cancer.
Erkasap N; Ozyurt R; Ozkurt M; Erkasap S; Yasar F; Ihtiyar E; Ciftci E; Canaz F; Colak E
Exp Ther Med; 2021 Jun; 21(6):600. PubMed ID: 33884038
[TBL] [Abstract][Full Text] [Related]
6. The vascular delta-like ligand-4 (DLL4)-Notch4 signaling correlates with angiogenesis in primary glioblastoma: an immunohistochemical study.
Zhang JF; Chen Y; Qiu XX; Tang WL; Zhang JD; Huang JH; Lin GS; Wang XF; Lin ZX
Tumour Biol; 2016 Mar; 37(3):3797-805. PubMed ID: 26472724
[TBL] [Abstract][Full Text] [Related]
7. Imbalance in leptin-adiponectin levels and leptin receptor expression as chief contributors to triple negative breast cancer progression in Northeast India.
Sultana R; Kataki AC; Borthakur BB; Basumatary TK; Bose S
Gene; 2017 Jul; 621():51-58. PubMed ID: 28414093
[TBL] [Abstract][Full Text] [Related]
8. Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer.
Liubomirski Y; Lerrer S; Meshel T; Morein D; Rubinstein-Achiasaf L; Sprinzak D; Wiemann S; Körner C; Ehrlich M; Ben-Baruch A
Front Immunol; 2019; 10():804. PubMed ID: 31105691
[TBL] [Abstract][Full Text] [Related]
9. Aberrant expression and clinical correlation of Notch signaling molecules in breast cancer of Chinese population.
Ma D; Dong X; Zang S; Ma R; Zhao P; Guo D; Dai J; Chen F; Ye J; Ji C
Asia Pac J Clin Oncol; 2011 Dec; 7(4):385-91. PubMed ID: 22151989
[TBL] [Abstract][Full Text] [Related]
10. Leptin's Pro-Angiogenic Signature in Breast Cancer.
Gonzalez-Perez RR; Lanier V; Newman G
Cancers (Basel); 2013 Sep; 5(3):1140-62. PubMed ID: 24202338
[TBL] [Abstract][Full Text] [Related]
11. Leptin pro-angiogenic signature in breast cancer is linked to IL-1 signalling.
Zhou W; Guo S; Gonzalez-Perez RR
Br J Cancer; 2011 Jan; 104(1):128-37. PubMed ID: 21139583
[TBL] [Abstract][Full Text] [Related]
12. Expression of NOTCH1, NOTCH4, HLA-DMA and HLA-DRA is synergistically associated with T cell exclusion, immune checkpoint blockade efficacy and recurrence risk in ER-negative breast cancer.
Liu D; Hofman P
Cell Oncol (Dordr); 2022 Jun; 45(3):463-477. PubMed ID: 35543859
[TBL] [Abstract][Full Text] [Related]
13. The presence and impact of estrogen metabolism on the biology of triple-negative breast cancer.
McNamara KM; Oguro S; Omata F; Kikuchi K; Guestini F; Suzuki K; Yang Y; Abe E; Hirakawa H; Brown KA; Takanori I; Ohuchi N; Sasano H
Breast Cancer Res Treat; 2017 Jan; 161(2):213-227. PubMed ID: 27848152
[TBL] [Abstract][Full Text] [Related]
14. Identification of key genes as potential biomarkers for triple‑negative breast cancer using integrating genomics analysis.
Zhong G; Lou W; Shen Q; Yu K; Zheng Y
Mol Med Rep; 2020 Feb; 21(2):557-566. PubMed ID: 31974598
[TBL] [Abstract][Full Text] [Related]
15. Leptin-cytokine crosstalk in breast cancer.
Newman G; Gonzalez-Perez RR
Mol Cell Endocrinol; 2014 Jan; 382(1):570-582. PubMed ID: 23562747
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.
Zhang Y; Dai J; McNamara KM; Bai B; Shi M; Chan MS; Liu M; Sasano H; Wang X; Li X; Liu L; Ma Y; Cao S; Xing Y; Zhao B; Song Y; Wang L
BMC Cancer; 2015 Oct; 15():699. PubMed ID: 26472563
[TBL] [Abstract][Full Text] [Related]
17. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals.
Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
Cancer Lett; 2017 Feb; 386():12-23. PubMed ID: 27836733
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
19. NOTCH4 is a potential therapeutic target for triple-negative breast cancer.
Nagamatsu I; Onishi H; Matsushita S; Kubo M; Kai M; Imaizumi A; Nakano K; Hattori M; Oda Y; Tanaka M; Katano M
Anticancer Res; 2014 Jan; 34(1):69-80. PubMed ID: 24403446
[TBL] [Abstract][Full Text] [Related]
20. Regulator of G protein signaling 20 correlates with clinicopathological features and prognosis in triple-negative breast cancer.
Li Q; Jin W; Cai Y; Yang F; Chen E; Ye D; Wang Q; Guan X
Biochem Biophys Res Commun; 2017 Apr; 485(3):693-697. PubMed ID: 28237701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
